Observational Study of Safety and Tolerability of Levemir™ FlexPen™ (Insulin Detemir) in the Treatment of Type 1 and Type 2 Diabetes Mellitus

Inclusion Criteria: * Patients diagnosed with Type 1 or Type 2 Diabetes Mellitus. * Newly diagnosed insulin naive patients * Patients currently on human insulin or on basal insulin * Patients prescribed with Levemir™ FlexPen™ (Insulin Detemir) therapy * Usage should be in accordance with the current prescribing information (See attached prescribing information) Exclusion Criteria: * Previous history of hypersensitivity to Insulin Detemir (Levemir™) and its excipients (See attached prescribing information) * Contraindications and warnings specified in the current prescribing information (See attached prescribing information) * Pregnant women, those planning to become pregnant, or women who are breastfeeding * Patients who are already on human premix or premix analogue (unless they are going to be shifted to basal-bolus therapy) * Children below 6 years old